Cost of Patients With Hemophilia A and High-Titer Inhibitors in Colombia

Background: In Colombia, hemophilia is considered a high-cost disease, and hemophilia A with high-titer inhibitors may be responsible for a significant economic pressure on the Colombian health system. Objectives: To estimate the direct cost of care for patients with hemophilia A with high-titer inh...

Full description

Autores:

Sánchez Vanegas, Guillermo
Linares, Adriana
Sarmiento, Isabel
Solano, María helena
Romano, Giancarlo
Castro, Carlos

Tipo de recurso:

Article of journal

Fecha de publicación:

2019

Institución:

Fundación Universitaria de Ciencias de la Salud - FUCS

Repositorio:

Repositorio Digital Institucional ReDi

Idioma:

eng

OAI Identifier:

oai:repositorio.fucsalud.edu.co:001/3164

Acceso en línea:

https://repositorio.fucsalud.edu.co/handle/001/3164

Palabra clave:

Cost of Illness
FVIII alloantibodies
Hemophilia A
Inhibitors
Prothrombin complex concentrates
Recombinant FVIIa
Costo de enfermedad
Isoanticuerpos
Inhibidores
Protrombina

Rights

openAccess

License

Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0)